Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1979 monotherapy in relapsed or refractory follicular lymphoma
2017-002139-41Phase 2Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odronextamab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective response rate. Started May 2019; status: active.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2017-002139-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002139-41.